Gynecologic Tumor Board–Case-Based Discussion of the Molecular & Treatment Approach Updates for the Management of Endometrial, Vulvar & Cervical Cancers

There have been many recent studies that further differentiate gynecologic cancers and their management relating to pathologic features, such as molecular status. Failure to be informed about these pathologic updates may result in over or under treatment of particular patients and therefore less optimized care.  

Using a multidisciplinary case-based approach, this activity discusses recent studies important for the management of gynecologic cancer. The activity includes a gynecologic pathologist for review and discussion of the significance of recent additions to gynecologic pathology reports that are becoming more common, including the four molecular groups and extent of lymphovascular invasion (LVI) for endometrial cancer, HPV status for vulvar cancer, and PD-L1 expression for cervical cancer. The endometrial case discussion highlights the updates in FIGO staging with the inclusion of molecular status and LVI, emerging data suggesting molecular status should influence treatment approach for endometrial cancers and role of immunotherapy for advanced stage disease. The vulvar and cervical cancer case discussions highlight how to use pathologic features, such as HPV status and PD-L1 expression to help guide treatment approach. Additionally, how to interpret recently reported contrasting data, in particular for immunotherapy and neoadjuvant chemotherapy, for locally advanced cervical cancer is reviewed to help optimize patient selection for these new treatment approaches for definitive management.  

Topics:

  1. Gynecologic Molecular Pathology Review for Endometrial, Vulvar and Cervical Cancers
    Taylor M. Jenkins, MD
  2. Endometrial Cancer Staging and Treatment Updates - The Significance of Pathology and Molecular Status
    Susan Elizabeth Gueble, MD, PhD
  3. Cervix and Vulvar Cases
    Junzo P. Chino, MD, FASTRO, FABS
  4. Q and A
    Malolan S. Rajagopalan, MD, MBA - Moderator
    Full Panel

This activity is available from March 4, 2025, through 11:59 p.m. Eastern time on March 3, 2027. 

The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, pathologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the molecular pathologic features that should be included in pathology report for endometrial, vulvar and cervix cancers.
  • Be able to discuss how pathologic factors, such as molecular status, influence prognosis and treatment decisions. 
  • Discuss recent clinical trial data for the management of gynecologic cancers and define what patient populations show survival benefits with these new approaches, such as immunotherapy. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
03/04/2025
Course expires: 
03/03/2027
Cost:
$0.00
Rating: 
0
  • Elizabeth A. Kidd, MD, is employed by Stanford University School of Medicine. Dr. Kidd serves in an uncompensated role as Co-Leader of the ABS Quality and Safety Standard Committee. 
  • Malolan S. Rajagopalan, MD, MBA, is employed by Radiology, Inc. 
  • Taylor M. Jenkins, MD, is employed by Virginia Commonwealth University. 
  • Susan Elizabeth Gueble, MD, PhD, is employed by Yale School of Medicine. Dr. Gueble receives grant/research funding from the NIH, Yale SPORE in Skin Cancer and the Spector Family Fund for Clinical Research and Investigation. Dr. Gueble receives royalties from Modifi Biosciences, Inc. Dr. Gueble is a member of the Yale Cancer Center Neuroendocrine Tumor Program Steering Committee. 
  • Junzo P. Chino, MD, FASTRO, FABS, is employed by Duke University Medical Center. Dr. Chino receives honoraria from KM Pharmaceutical Consulting LLC and Stryker. Dr. Chino is a Board member of the American Brachytherapy Society. 

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until March 3, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.